Abstract
Diabetic nephropathy is a serious complication of diabetes mellitus caused by metabolic and hemodynamic changes. Both supportive and drug therapies have been limited to treatment of cardiovascular risk factors and blockade of the renin–angiotensin–aldosterone system. With the development of sodium–glucose linked transporter 2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor blockers, two classes of drugs that suppress the proinflammatory and profibrotic nature of diabetic nephropathy are available after years of stagnation. In addition, glucagon-like peptide 1 (GLP-1) receptor agonists may soon expand the therapeutic portfolio. Atrasentan, selonsertib, and stimulators and activators of soluble guanylate cyclase present themselves as promising future therapeutic options.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
